Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Brenipatide

Stage Phase 1Stale

Sponsor Eli Lilly and Company

Route injection

Sources

registry, as of 2026-07-16Stale

https://clinicaltrials.gov/study/NCT07476118

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 150. Conditions Obesity; Overweight. The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in

ClinicalTrials.gov NCT07476118 protocol and results modules

Studies

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Registry NCT07476118

Phase Phase 1

Status Active, not recruiting

Enrollment 150

Start 2026-03-18

Brenipatide

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight